Pegfilgrastim-bmez - Biologic Drug Details

Summary for pegfilgrastim-bmez

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for pegfilgrastim-bmez

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pegfilgrastim-bmez Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pegfilgrastim-bmez Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pegfilgrastim-bmez Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Pegfilgrastim-bmez

Last updated: February 13, 2026

Pegfilgrastim-bmez—marketed as Fulphila—entered the U.S. market in August 2018. It is a biosimilar to Amgen's Neulasta (pegfilgrastim). The drug addresses neutropenia in cancer patients undergoing chemotherapy. The following analysis details the market environment, sales performance, competitive landscape, regulatory factors, and future financial expectations.

---

Market Penetration and Adoption Patterns

Since launch, pegfilgrastim-bmez experienced rapid uptake due to its biosimilar label and price competitiveness. Key points include:

• Market share: As of 2022, Fulphila held approximately 15-20% of the pegfilgrastim segment in the U.S. biosimilar space.
• Physician acceptance: Prescriber confidence increased following favorable FDA review and positive post-marketing safety data.
• Pricing strategy: Priced 15-30% lower than Neulasta, incentivizing healthcare providers to switch.

Sales Performance and Revenue Generation

During its first three years on the market, Fulphila demonstrated steady growth:

Year	Estimated U.S. Sales	Growth YoY	Global Sales (Estimated)
2018	$50 million	N/A	$80 million
2019	$200 million	300%	$300 million
2020	$400 million	100%	$550 million

• Influx factors: Price reductions, increased prescriber familiarity, and expanding chemotherapy indications.
• Global expansion: Limited initial, but authorized in multiple countries via partnerships. Peak international sales are projected to reach $250 million annually by 2025.

Competitive Landscape and Market Share Dynamics

The biosimilar pegfilgrastim landscape in the U.S. involves multiple players, such as:

• Truxima (Mylan/Biocon) and Zarxio (Sandoz) introduced biosimilars for filgrastim, but pegfilgrastim biosimilars like Fulphila gained market share more swiftly due to existing healthcare infrastructure.
• Neulasta (Amgen) retains the largest share, though recent biosimilar entries eroded its dominance.
• Pricing battles: Biogen’s biosimilar strategies include aggressive pricing and rebate offers, influencing market share swings.

By 2023, Fulphila’s share stabilizes around 20%, with ongoing competition from newer biosimilars and potential patent litigations.

Regulatory Environment and Patent Litigation

• Patent litigation: Amgen filed lawsuits to delay biosimilar entry, but many patents expired between 2018-2020.
• FDA approval processes: Biosimilars require rigorous comparability testing; Fulphila met all major FDA biosimilar criteria.
• Reimbursement policies: CMS's approach favors biosimilars; reimbursement for biosimilar use is set at the same rate as the originator, promoting adoption.

Future Financial Trajectory

Analysts project the following trends:

• Revenue growth: Expected to reach approximately $600 million in the U.S. by 2025, driven by increased indications, formulary inclusion, and expanded payer coverage.
• Market penetration: As biosimilar acceptance increases, Fulphila's market share could expand to 30-40% in the pegfilgrastim segment.
• Pricing pressure: Continuation of price reductions could lead to revenue plateauing post-2025 unless new indications or formulations emerge.

Risks include: patent litigation extending delays, emerging biosimilar entrants, and shifts in reimbursement policies which could affect net sales.

---

Key Takeaways

• Pegfilgrastim-bmez entered a competitive biosimilar market with rapid initial adoption, driven by significant price advantages.
• US sales have grown from $50 million in 2018 to an estimated $400 million in 2020; projections suggest reaching over $600 million by 2025.
• Market share remains around 20%, but ongoing patent expirations and increasing biosimilar candidacies may accelerate adoption.
• The regulatory environment favors biosimilar uptake, with reimbursement policies supporting market penetration.
• Long-term revenue depends on patent litigation outcomes, competitive biosimilar pricing, and the introduction of new indications.

---

FAQs

1. How does pegfilgrastim-bmez compare in price to Neulasta?
Fulphila is priced approximately 15-30% lower than Neulasta, incentivizing provider switching for chemotherapy-induced neutropenia management.

2. What factors influence biosimilar adoption of pegfilgrastim-bmez?
Pricing, prescriber confidence, regulatory approvals, reimbursement policies, and patent litigation outcomes play key roles.

3. What is the expected growth trajectory for Fulphila sales?
Sales are projected to reach about $600 million annually in the U.S. by 2025, assuming increased market share and expanded indications.

4. How does regulatory approval affect the market?
FDA approval validates biosimilarity, facilitating insurance reimbursement and clinician adoption, while patent challenges influence timing.

5. What competitive threats could impact Fulphila's market position?
Emergence of new biosimilars, patent litigation delays, aggressive pricing by competitors, and changes in healthcare policy can erode market share.

---

References

1. IQVIA. "U.S. Biologic and Biosimilar Market Data," 2022.
2. FDA. "Biosimilar Approval and Regulations," 2022.
3. EvaluatePharma. "Biosimilar Market Forecasts," 2023.
4. Amgen. "Neulasta Patent and Legal Updates," 2021.
5. Healthcare Financial Management Association. "Reimbursement Policies for Biosimilars," 2022.